Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 33 articles: HTML format

Single Articles

May 2023
1. KAMIYA S, Nakamori Y, Takasawa A, Takasawa K, et al
   Suppression of the vitamin D metabolizing enzyme CYP24A1 provides increased sensitivity to chemotherapeutic drugs in breast cancer.
   Oncol Rep. 2023;49:85.
   PubMed     Abstract available
   
   
   April 2023
2. PAN C, Shao S, Gu Y, Ni Q, et al
   Radiation prevents tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑kappaB pathway in triple‑negative breast cancer.
   Oncol Rep. 2023;49:78.
   PubMed     Abstract available
   
   
   March 2023
3. HAN S, Jin X, Hu T, Chi F, et al
   LAPTM5 regulated by FOXP3 promotes the malignant phenotypes of breast cancer through activating the Wnt/beta‑catenin pathway.
   Oncol Rep. 2023;49:60.
   PubMed     Abstract available
   
   
   February 2023
4. VELEZ BC, Petrella CP, DiSalvo KH, Cheng K, et al
   Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion.
   Oncol Rep. 2023;49:32.
   PubMed     Abstract available
   
   
   
5. LIM JS, Kyung SY, Jeon Y, Kim IS, et al
   Anticancer effects of the HDAC inhibitor, 3beta,6beta‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways.
   Oncol Rep. 2023;49:43.
   PubMed     Abstract available
   
   
   January 2023
6. BONTEMPS I, Lallemand C, Biard D, Dechamps N, et al
   Loss of CD24 promotes radiation and chemoresistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.
   Oncol Rep. 2023;49.
   PubMed     Abstract available
   
   
   November 2022
7. ARMANDO R, Cabrera M, Vilarullo R, Chinestrad P, et al
   In vitro characterization and rational analog design of a novel inhibitor of telomerase assembly in MDA MB 231 breast cancer cell line.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   
8. JIANG H, Li X, Wang W, Hu Y, et al
   MYCL promotes the progression of triplenegative breast cancer by activating the JAK/STAT3 pathway.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   October 2022
9. HU H, Xiang Y, Zhang XY, Deng Y, et al
   CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   September 2022
10. ZHUANG Y, Li X, Zhan P, Pi G, et al
    HIF1alpha and MBP1 are associated with the progression of breast cancer cells by repressing betacatenin transcription.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    July 2022
11. SUI Y, Zhang X, Yang H, Wei W, et al
    [Retracted] MicroRNA133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
12. JIRAPONGWATTANA N, Thongchot S, Chiraphapphaiboon W, Chieochansin T, et al
    Mesothelinspecific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3treated selfdifferentiated dendritic cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
13. HAM A, Cho MH, Won HS, Jo J, et al
    betacatenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrineresistant breast cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    June 2022
14. JIANG Q, He M, Ma MT, Wu HZ, et al
    [Corrigendum] MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
15. LI J, Liu L, Chen Y, Wu M, et al
    Ribosome assembly factor PNO1 is associated with progression and promotes tumorigenesis in triplenegative breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
16. TAKEDA T, Tsubaki M, Matsuda T, Kimura A, et al
    EGFR inhibition reverses epithelialmesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    May 2022
17. TSAO AN, Chuang YS, Lin YC, Su Y, et al
    Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    March 2022
18. ZHANG H, Wei N, Zhang W, Shen L, et al
    [Retracted] lncRNA SNHG3 promotes breast cancer progression by acting as a miR326 sponge.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
19. CHEN Y, Wei L, Zhang X, Liu X, et al
    [Corrigendum] 3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
20. CAO W, Shen R, Richard S, Liu Y, et al
    Inhibition of triplenegative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
21. INAISHI T, Shibata M, Ichikawa T, Kanda M, et al
    Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
22. TORNROOS R, Tina E, Gothlin Eremo A
    SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogenreceptorpositive breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    December 2021
23. KIM JM, Park J, Noh EM, Song HK, et al
    Downregulation of matriptase suppresses the PAR2/PLCgamma2/PKCmediated invasion and migration abilities of MCF7 breast cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
24. THONGCHOT S, Jamjuntra P, Prasopsiri J, Thuwajit P, et al
    Establishment and characterization of novel highly aggressive HER2positive and triplenegative breast cancer cell lines.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    November 2021
25. JEON SM, Lim JS, Park SH, Lee JH, et al
    Wnt signaling promotes tumor development in part through phosphofructokinase 1 platelet isoform upregulation.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
26. CHIU YJ, Tsai FJ, Bau DT, Chang LC, et al
    Nextgeneration sequencing analysis reveals that MTH3, a novel curcuminoid derivative, suppresses the invasion of MDAMB231 triplenegative breast adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    May 2021
27. TREMANTE E, Sibilio L, Centola F, Knutti N, et al
    TOOLBOX: StrepTagged nanoassemblies of antibodydrugconjugates (ADC) for modular and conditional cancer drugging
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    April 2021
28. CALAF GM, Bleak TC, Roy D
    Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    March 2021
29. XU X, Liu M, Yang Y, Wei C, et al
    VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARgamma/AMPK signaling pathway.
    Oncol Rep. 2021;45:975-986.
    PubMed     Abstract available
    
    
    
30. AN SQ, He K, Liu F, Ding QS, et al
    Low microRNA150 expression is associated with activated carcinogenic pathways and a poor prognosis in patients with breast cancer.
    Oncol Rep. 2021;45:1235-1248.
    PubMed     Abstract available
    
    
    
31. CHEN H, Sun Y, Yang Z, Yin S, et al
    Metabolic heterogeneity and immunocompetence of infiltrating immune cells in the breast cancer microenvironment (Review).
    Oncol Rep. 2021;45:846-856.
    PubMed     Abstract available
    
    
    
32. NAKANISHI M, Korechika A, Yamakawa H, Kawabe N, et al
    Acidic microenvironment induction of interleukin-8 expression and matrix metalloproteinase-2/-9 activation via acid-sensing ion channel 1 promotes breast cancer cell progression.
    Oncol Rep. 2021;45:1284-1294.
    PubMed     Abstract available
    
    
    February 2021
33. LU N, Zhang M, Lu L, Liu YZ, et al
    miRNA4903p promotes the metastatic progression of invasive ductal carcinoma.
    Oncol Rep. 2021;45:706-716.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: